# Oracle Corp: financial statements, quarterly

ORCL · NYSE · CIK 1341439 · [Technology](/sectors/technology.md) · fiscal year ends May 31

Pages: [Overview](/companies/orcl.md) · [Financials](/companies/orcl/financials.md) · [Filings](/companies/orcl/filings.md) · [Insiders](/companies/orcl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/orcl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [12.9](/filings/0000950170-24-134973.md) | [13.3](/filings/0000950170-25-037143.md) | [14.3 d](/filings/0001193125-26-277521.md) | [13.3](/filings/0001193125-25-200095.md) | [14.1](/filings/0001193125-25-315925.md) | [14.1](/filings/0001193125-26-101045.md) | [15.9 d](/filings/0001193125-26-277521.md) | [14.9](/filings/0001193125-26-389274.md) | [16.1](/filings/0001193125-25-315925.md) | [17.2](/filings/0001193125-26-101045.md) | [19.2 d](/filings/0001193125-26-277521.md) | [19.3](/filings/0001193125-26-389274.md) |
| Cost of revenue | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $bn | [2.2](/filings/0000950170-24-134973.md) | [2.2](/filings/0000950170-25-037143.md) | [2.2 d](/filings/0001193125-26-277521.md) | [2.3](/filings/0001193125-25-200095.md) | [2.5](/filings/0001193125-25-315925.md) | [2.4](/filings/0001193125-26-101045.md) | [2.7 d](/filings/0001193125-26-277521.md) | [2.5](/filings/0001193125-26-389274.md) | [2.6](/filings/0001193125-25-315925.md) | [2.6](/filings/0001193125-26-101045.md) | [2.6 d](/filings/0001193125-26-277521.md) | [2.4](/filings/0001193125-26-389274.md) |
| Operating income | $bn | [3.6](/filings/0000950170-24-134973.md) | [3.8](/filings/0000950170-25-037143.md) | [4.7 d](/filings/0001193125-26-277521.md) | [4.0](/filings/0001193125-25-200095.md) | [4.2](/filings/0001193125-25-315925.md) | [4.4](/filings/0001193125-26-101045.md) | [5.1 d](/filings/0001193125-26-277521.md) | [4.3](/filings/0001193125-26-389274.md) | [4.7](/filings/0001193125-25-315925.md) | [5.5](/filings/0001193125-26-101045.md) | [6.1 d](/filings/0001193125-26-277521.md) | [6.7](/filings/0001193125-26-389274.md) |
| Interest expense | $bn | [0.9](/filings/0000950170-24-134973.md) | [0.9](/filings/0000950170-25-037143.md) | [0.9 d](/filings/0001193125-26-277521.md) | [0.8](/filings/0001193125-25-200095.md) | [0.9](/filings/0001193125-25-315925.md) | [0.9](/filings/0001193125-26-101045.md) | [1.0 d](/filings/0001193125-26-277521.md) | [0.9](/filings/0001193125-26-389274.md) | [1.1](/filings/0001193125-25-315925.md) | [1.2](/filings/0001193125-26-101045.md) | [1.4 d](/filings/0001193125-26-277521.md) | [1.4](/filings/0001193125-26-389274.md) |
| Income tax | $bn | [0.2](/filings/0000950170-24-134973.md) | [0.5](/filings/0000950170-25-037143.md) | [0.6 d](/filings/0001193125-26-277521.md) | [0.2](/filings/0001193125-25-200095.md) | [0.2](/filings/0001193125-25-315925.md) | [0.5](/filings/0001193125-26-101045.md) | [0.7 d](/filings/0001193125-26-277521.md) | [0.5](/filings/0001193125-26-389274.md) | [0.2](/filings/0001193125-25-315925.md) | [0.7](/filings/0001193125-26-101045.md) | [1.1 d](/filings/0001193125-26-277521.md) | [0.8](/filings/0001193125-26-389274.md) |
| Net income | $bn | [2.5](/filings/0000950170-24-134973.md) | [2.4](/filings/0000950170-25-037143.md) | [3.1 d](/filings/0001193125-26-277521.md) | [2.9](/filings/0001193125-25-200095.md) | [3.2](/filings/0001193125-25-315925.md) | [2.9](/filings/0001193125-26-101045.md) | [3.4 d](/filings/0001193125-26-277521.md) | [2.9](/filings/0001193125-26-389274.md) | [6.1](/filings/0001193125-25-315925.md) | [3.7](/filings/0001193125-26-101045.md) | [4.3 d](/filings/0001193125-26-277521.md) | [4.8](/filings/0001193125-26-389274.md) |
| Diluted EPS | $ per share | [0.89](/filings/0000950170-24-134973.md) | [0.85](/filings/0000950170-25-037143.md) | not reported | [1.03](/filings/0001193125-25-200095.md) | [1.10](/filings/0001193125-25-315925.md) | [1.02](/filings/0001193125-26-101045.md) | not reported | [1.01](/filings/0001193125-26-389274.md) | [2.10](/filings/0001193125-25-315925.md) | [1.27](/filings/0001193125-26-101045.md) | not reported | [1.56](/filings/0001193125-26-389274.md) |
| Basic EPS | $ per share | [0.91](/filings/0000950170-24-134973.md) | [0.87](/filings/0000950170-25-037143.md) | not reported | [1.06](/filings/0001193125-25-200095.md) | [1.13](/filings/0001193125-25-315925.md) | [1.05](/filings/0001193125-26-101045.md) | not reported | [1.04](/filings/0001193125-26-389274.md) | [2.14](/filings/0001193125-25-315925.md) | [1.29](/filings/0001193125-26-101045.md) | not reported | [1.58](/filings/0001193125-26-389274.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [8.2](/filings/0000950170-23-069682.md) | [9.5](/filings/0000950170-24-029904.md) | [10.5](/filings/0000950170-25-087926.md) | [10.6](/filings/0000950170-24-104905.md) | [10.9](/filings/0000950170-24-134973.md) | [17.4](/filings/0000950170-25-037143.md) | [10.8](/filings/0001193125-26-277521.md) | [10.4](/filings/0001193125-25-200095.md) | [19.2](/filings/0001193125-25-315925.md) | [38.5](/filings/0001193125-26-101045.md) | [31.3](/filings/0001193125-26-389274.md) | [36.4](/filings/0001193125-26-389274.md) |
| Current assets | $bn | [19.3](/filings/0000950170-23-069682.md) | [21.1](/filings/0000950170-24-029904.md) | [22.6](/filings/0000950170-25-087926.md) | [23.1](/filings/0000950170-24-104905.md) | [23.5](/filings/0000950170-24-134973.md) | [30.1](/filings/0000950170-25-037143.md) | [24.6](/filings/0001193125-26-277521.md) | [24.6](/filings/0001193125-25-200095.md) | [34.4](/filings/0001193125-25-315925.md) | [54.9](/filings/0001193125-26-101045.md) | [46.6](/filings/0001193125-26-389274.md) | [55.6](/filings/0001193125-26-389274.md) |
| Total assets | $bn | [134](/filings/0000950170-23-069682.md) | [137](/filings/0000950170-24-029904.md) | [141](/filings/0000950170-25-087926.md) | [144](/filings/0000950170-24-104905.md) | [148](/filings/0000950170-24-134973.md) | [161](/filings/0000950170-25-037143.md) | [168](/filings/0001193125-26-277521.md) | [180](/filings/0001193125-25-200095.md) | [205](/filings/0001193125-25-315925.md) | [245](/filings/0001193125-26-101045.md) | [262](/filings/0001193125-26-389274.md) | [303](/filings/0001193125-26-389274.md) |
| Current liabilities | $bn | [24.4](/filings/0000950170-23-069682.md) | [24.9](/filings/0000950170-24-029904.md) | [31.5](/filings/0000950170-25-087926.md) | [32.0](/filings/0000950170-24-104905.md) | [29.1](/filings/0000950170-24-134973.md) | [29.6](/filings/0000950170-25-037143.md) | [32.6](/filings/0001193125-26-277521.md) | [39.9](/filings/0001193125-25-200095.md) | [37.8](/filings/0001193125-25-315925.md) | [40.7](/filings/0001193125-26-101045.md) | [41.8](/filings/0001193125-26-389274.md) | [47.5](/filings/0001193125-26-389274.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $bn | not reported | not reported | [10.6](/filings/0000950170-25-087926.md) | not reported | not reported | not reported | [7.3](/filings/0001193125-26-277521.md) | not reported | not reported | not reported | [7.2](/filings/0001193125-26-277521.md) | not reported |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [3.9](/filings/0000950170-23-069682.md) | [5.6](/filings/0000950170-24-029904.md) | [8.7](/filings/0000950170-25-087926.md) | [10.8](/filings/0000950170-24-104905.md) | [13.7](/filings/0000950170-24-134973.md) | [16.7](/filings/0000950170-25-037143.md) | [20.5](/filings/0001193125-26-277521.md) | [24.2](/filings/0001193125-25-200095.md) | [30.0](/filings/0001193125-25-315925.md) | [38.5](/filings/0001193125-26-101045.md) | [42.5](/filings/0001193125-26-389274.md) | [66.8](/filings/0001193125-26-389274.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $bn | [0.1 d](/filings/0000950170-24-134973.md) | [5.5 d](/filings/0000950170-25-037143.md) | [6.1 d](/filings/0001193125-26-277521.md) | [7.4](/filings/0001193125-25-200095.md) | [1.3 d](/filings/0001193125-25-315925.md) | [5.9 d](/filings/0001193125-26-101045.md) | [6.2 d](/filings/0001193125-26-277521.md) | [8.1](/filings/0001193125-26-389274.md) | [2.1 d](/filings/0001193125-25-315925.md) | [7.2 d](/filings/0001193125-26-101045.md) | [14.6 d](/filings/0001193125-26-277521.md) | [23.1](/filings/0001193125-26-389274.md) |
| Capital expenditure | $bn | [1.1 d](/filings/0000950170-24-134973.md) | [1.7 d](/filings/0000950170-25-037143.md) | [2.8 d](/filings/0001193125-26-277521.md) | [2.3](/filings/0001193125-25-200095.md) | [4.0 d](/filings/0001193125-25-315925.md) | [5.9 d](/filings/0001193125-26-101045.md) | [9.1 d](/filings/0001193125-26-277521.md) | [8.5](/filings/0001193125-26-389274.md) | [12.0 d](/filings/0001193125-25-315925.md) | [18.6 d](/filings/0001193125-26-101045.md) | [16.5 d](/filings/0001193125-26-277521.md) | [28.5](/filings/0001193125-26-389274.md) |
| Dividends paid | $bn | [1.1 d](/filings/0000950170-24-134973.md) | [1.1 d](/filings/0000950170-25-037143.md) | [1.1 d](/filings/0001193125-26-277521.md) | [1.1](/filings/0001193125-25-200095.md) | [1.1 d](/filings/0001193125-25-315925.md) | [1.1 d](/filings/0001193125-26-101045.md) | [1.4 d](/filings/0001193125-26-277521.md) | [1.4](/filings/0001193125-26-389274.md) | [1.4 d](/filings/0001193125-25-315925.md) | [1.4 d](/filings/0001193125-26-101045.md) | [1.5 d](/filings/0001193125-26-277521.md) | [1.6](/filings/0001193125-26-389274.md) |
| Share repurchases | $bn | [0.5 d](/filings/0000950170-24-134973.md) | [0.5 d](/filings/0000950170-25-037143.md) | [0.2 d](/filings/0001193125-26-277521.md) | [0.2](/filings/0001193125-25-200095.md) | [0.2 d](/filings/0001193125-25-315925.md) | [0.2 d](/filings/0001193125-26-101045.md) | [0.2 d](/filings/0001193125-26-277521.md) | [0.1](/filings/0001193125-25-200095.md) | [0.0 d](/filings/0001193125-25-315925.md) | [0.0 d](/filings/0001193125-26-101045.md) | [0.0 d](/filings/0001193125-26-277521.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-11-30) | Q3 FY2023 (2023-02-28) | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2,746](/filings/0000950170-23-069682.md) | [2,776](/filings/0000950170-24-029904.md) | [2,823](/filings/0000950170-24-104905.md) | [2,817](/filings/0000950170-24-134973.md) | [2,819](/filings/0000950170-25-037143.md) | [2,851](/filings/0001193125-25-200095.md) | [2,869](/filings/0001193125-25-315925.md) | [2,874](/filings/0001193125-26-101045.md) | [2,909](/filings/0001193125-26-389274.md) | [2,922](/filings/0001193125-25-315925.md) | [2,912](/filings/0001193125-26-101045.md) | [3,000](/filings/0001193125-26-389274.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,023,736,000 at 2026-09-07, from the cover of the [10-Q filed 2026-09-11](/filings/0001193125-26-389274.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.